Facial palsy Revealing AR+/HER2+ Parotid carcinoma and the efficacy of HER2-Targeted therapy trastuzumab deruxtecan.

Authors

Tiffany Ng, Momilani Tupu, Naidelin Maldonado, Rahul Patel, Julia Reitkopp, Kyaw Zin Thein

Published in

Oral oncology. Volume 182. Pages 108128. Sep 05, 2026. Epub Sep 05, 2026.

Abstract

Salivary duct carcinomas present challenges to diagnosis and treatment due to diversity in histopathology and clinical behavior (Laurie & Licitra, 2006; Seethala, 2009). A 76-year-old male presented with gradual left-sided facial weakness that was discovered to be left parotid malignant salivary gland carcinoma. Treatment with fam-trastuzumab deruxtecan-nxki, a HER2-directed antibody-drug conjugate, produced a favorable response. Results support an emerging "HER2-low" treatment protocol across diverse salivary gland malignancies.

PMID:
42700519
Bibliographic data and abstract were imported from PubMed on 06 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.